Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
126,468,243
-
Total 13F shares
-
57,408,855
-
Share change
-
-1,660,353
-
Total reported value
-
$334,396,841
-
Put/Call ratio
-
501%
-
Price per share
-
$5.82
-
Number of holders
-
130
-
Value change
-
-$25,823,482
-
Number of buys
-
69
-
Number of sells
-
63
Institutional Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q3 2021
As of 30 Sep 2021,
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) was held by
130 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
57,408,855 shares.
The largest 10 holders included
BlackRock Inc., STATE STREET CORP, Palo Alto Investors LP, VANGUARD GROUP INC, Rubric Capital Management LP, Delphi Management Partners VIII, L.L.C., ALKEON CAPITAL MANAGEMENT LLC, MORGAN STANLEY, Lombard Odier Asset Management (Switzerland) SA, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
130
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.